Abstract
Background Minorities have demonstrated an increased risk for type II endometrial cancers, but no data exists about risk among minority subpopulations. Our objective was to evaluate heterogeneity in risk of type II endometrial cancer (EC) histologies across race and Hispanic sub-groups using data from Florida's statewide cancer registry (FCDS). Methods FCDS contains data on N = 26,416 women diagnosed with EC from 2004 to 2013. Our analysis included women ≥ 18 years of age who were classified as non-Hispanic White (NHW), non-Hispanic Black (NHB) or belonged to one of five Hispanic sub-groups, and had a histology code consistent with type I or type II EC. Binary logistic regression analyses were performed to model risk of type II versus type I ECs across racial and ethnic groups relative to NHW. Results Relative to NHW, overall odds of being diagnosed with a type II EC were significantly higher in NHB (OR = 2.64, 95%CI: 2.38–2.92), Cubans (OR = 1.35, 95%CI: 1.08–1.68) and South and Central Americans (SCA) (OR = 1.84, 95%CI: 1.40–2.43). Compared to NHW, odds of serous EC were significantly higher in Cubans (OR = 2.15, 95% CI: 1.51–3.05) and NHB (OR = 2.51, 95% CI: 2.11–2.97); odds of carcinosarcoma (CS) were significantly higher in NHB (OR = 2.97, 95% CI: 2.47–3.57) and Puerto Ricans (OR = 2.35, 95%CI: 1.32–4.17); and odds of grade III adenocarcinoma (AG3) were significantly higher in NHB (OR = 1.60, 95% CI: 1.42–1.81) and SCA (OR = 1.76, 95%CI: 1.29–2.40). Conclusion Risk of type II EC varies considerably across Hispanic sub-groups, with Cubans, Puerto Ricans and SCA characterized by elevated odds for specific type II histologies.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 329-333 |
| Number of pages | 5 |
| Journal | Gynecologic Oncology |
| Volume | 147 |
| Issue number | 2 |
| DOIs | |
| State | Published - Nov 1 2017 |
Fingerprint
Keywords
- Carcinoma
- Endometrial cancer
- Hispanics
- Incidence
- Risk
ASJC Scopus subject areas
- Oncology
- Obstetrics and Gynecology
Cite this
Variation in type II endometrial cancer risk by Hispanic subpopulation : An exploratory analysis. / Schlumbrecht, Matthew; Baeker Bispo, Jordan A.; Balise, Raymond; Huang, Marilyn; Slomovitz, Brian; Kobetz, Erin.
In: Gynecologic Oncology, Vol. 147, No. 2, 01.11.2017, p. 329-333.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Variation in type II endometrial cancer risk by Hispanic subpopulation
T2 - An exploratory analysis
AU - Schlumbrecht, Matthew
AU - Baeker Bispo, Jordan A.
AU - Balise, Raymond
AU - Huang, Marilyn
AU - Slomovitz, Brian
AU - Kobetz, Erin
PY - 2017/11/1
Y1 - 2017/11/1
N2 - Background Minorities have demonstrated an increased risk for type II endometrial cancers, but no data exists about risk among minority subpopulations. Our objective was to evaluate heterogeneity in risk of type II endometrial cancer (EC) histologies across race and Hispanic sub-groups using data from Florida's statewide cancer registry (FCDS). Methods FCDS contains data on N = 26,416 women diagnosed with EC from 2004 to 2013. Our analysis included women ≥ 18 years of age who were classified as non-Hispanic White (NHW), non-Hispanic Black (NHB) or belonged to one of five Hispanic sub-groups, and had a histology code consistent with type I or type II EC. Binary logistic regression analyses were performed to model risk of type II versus type I ECs across racial and ethnic groups relative to NHW. Results Relative to NHW, overall odds of being diagnosed with a type II EC were significantly higher in NHB (OR = 2.64, 95%CI: 2.38–2.92), Cubans (OR = 1.35, 95%CI: 1.08–1.68) and South and Central Americans (SCA) (OR = 1.84, 95%CI: 1.40–2.43). Compared to NHW, odds of serous EC were significantly higher in Cubans (OR = 2.15, 95% CI: 1.51–3.05) and NHB (OR = 2.51, 95% CI: 2.11–2.97); odds of carcinosarcoma (CS) were significantly higher in NHB (OR = 2.97, 95% CI: 2.47–3.57) and Puerto Ricans (OR = 2.35, 95%CI: 1.32–4.17); and odds of grade III adenocarcinoma (AG3) were significantly higher in NHB (OR = 1.60, 95% CI: 1.42–1.81) and SCA (OR = 1.76, 95%CI: 1.29–2.40). Conclusion Risk of type II EC varies considerably across Hispanic sub-groups, with Cubans, Puerto Ricans and SCA characterized by elevated odds for specific type II histologies.
AB - Background Minorities have demonstrated an increased risk for type II endometrial cancers, but no data exists about risk among minority subpopulations. Our objective was to evaluate heterogeneity in risk of type II endometrial cancer (EC) histologies across race and Hispanic sub-groups using data from Florida's statewide cancer registry (FCDS). Methods FCDS contains data on N = 26,416 women diagnosed with EC from 2004 to 2013. Our analysis included women ≥ 18 years of age who were classified as non-Hispanic White (NHW), non-Hispanic Black (NHB) or belonged to one of five Hispanic sub-groups, and had a histology code consistent with type I or type II EC. Binary logistic regression analyses were performed to model risk of type II versus type I ECs across racial and ethnic groups relative to NHW. Results Relative to NHW, overall odds of being diagnosed with a type II EC were significantly higher in NHB (OR = 2.64, 95%CI: 2.38–2.92), Cubans (OR = 1.35, 95%CI: 1.08–1.68) and South and Central Americans (SCA) (OR = 1.84, 95%CI: 1.40–2.43). Compared to NHW, odds of serous EC were significantly higher in Cubans (OR = 2.15, 95% CI: 1.51–3.05) and NHB (OR = 2.51, 95% CI: 2.11–2.97); odds of carcinosarcoma (CS) were significantly higher in NHB (OR = 2.97, 95% CI: 2.47–3.57) and Puerto Ricans (OR = 2.35, 95%CI: 1.32–4.17); and odds of grade III adenocarcinoma (AG3) were significantly higher in NHB (OR = 1.60, 95% CI: 1.42–1.81) and SCA (OR = 1.76, 95%CI: 1.29–2.40). Conclusion Risk of type II EC varies considerably across Hispanic sub-groups, with Cubans, Puerto Ricans and SCA characterized by elevated odds for specific type II histologies.
KW - Carcinoma
KW - Endometrial cancer
KW - Hispanics
KW - Incidence
KW - Risk
UR - http://www.scopus.com/inward/record.url?scp=85028757963&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85028757963&partnerID=8YFLogxK
U2 - 10.1016/j.ygyno.2017.09.002
DO - 10.1016/j.ygyno.2017.09.002
M3 - Article
C2 - 28888539
AN - SCOPUS:85028757963
VL - 147
SP - 329
EP - 333
JO - Gynecologic Oncology
JF - Gynecologic Oncology
SN - 0090-8258
IS - 2
ER -